DOI: https://doi.org/10.52379/mcs.v10.615

Trend in seroprevalence of hepatitis B virus markers in donors from Paraguay from 2012 to 2023. A retrospective approach at the national level

Authors

  • Nathalia Navarro Universidad Nacional de Asunción. Facultad de Ciencias Químicas. Departamento de Bioquímica Clínica.
  • Margarita Samudio University of the Pacific image/svg+xml , Universidad del Pacífico image/svg+xml , Pacific University image/svg+xml , University of the Pacific image/svg+xml , University of the Pacific image/svg+xml
  • Nelson Marqués Roa Ministerio de Salud Pública y Bienestar Social. Programa Nacional de Sangre
  • Anibal Espínola Cano Universidad Nacional de Asunción. Instituto de Investigaciones en Ciencias de la Salud. Asunción, Paraguay
  • Jimena Casco Cantero Universidad Nacional de Asunción. Facultad de Ciencias Químicas. Departamento de Bioquímica Clínica
  • Cecilia Gonzalez1 Vatteone Universidad Nacional de Asunción. Facultad de Ciencias Químicas. Departamento de Bioquímica Clínica.
  • Pamela Mancuello Universidad Nacional de Asunción. Facultad de Ciencias Químicas. Departamento de Bioquímica Clínica.
  • Leticia Rufinelli Arce Universidad Nacional de Asunción. Facultad de Ciencias Químicas. Departamento de Bioquímica Clínica.
  • Amanda Carolina Molas Ministerio de Salud Pública y Bienestar Social. Programa Nacional de Sangre

Keywords:

Hepatitis B, Seroprevalence, trend, blood donors

Abstract

Introduction: Hepatitis B virus infection has been declared a major public health problem by the World Health Organization. It is a potentially fatal disease. Preventing transmission through blood transfusions presents one of the greatest challenges; therefore, serological and molecular screening is performed to minimize risks. Objective: To evaluate the seroprevalence trend of hepatitis B virus markers in donors from Paraguay. Methodology: A retrospective cross-sectional descriptive study was carried out in which the seroprevalences of the central antigen (anti-HBc) and surface antigen (HBsAg) of the hepatitis B virus of adult donors registered in the National Blood Services System of Paraguay in the period 2012-2023 were analyzed. Results: From 2012 to 2023, 1.165.486 blood units were collected. The overall seroprevalence for the HBsAg marker was 0.33% (n=43,834), with a stable trend over time (r2=0.05; p=0.504). For the Anti-HBc antibody, the overall seroprevalence was 2.38% (n=27,707), with a downward trend (r2=0.80; p<0.001). Conclusion: Despite the stable and downward trends in reported seroprevalence in donors, the importance of centralizing data at the national level, the use of highly sensitive and specific detection tests, and the need to adopt preventive measures such as immunization in donors are highlighted.

Downloads

Download data is not yet available.

References

1. World Health Organization. Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations. Geneva: World Health Organization; 2016. https://www.who.int/publications/i/item/9789241540391

2. World Health Organization. Monitoring and evaluation for viral hepatitis B and C: recommended indicators and framework. Technical report. Geneva: World Health Organization; 2016. https://www.who.int/publications/i/item/9789241510288

3. Moualem S, Farhat A, Youssef LA. Seroprevalence and trends of hepatitis B virus, hepatitis C virus and human immunodeficiency virus in Syrian blood donors at Damascus University Blood Center between 2004 and 2021. Front Public Health. 2023;11:1174638. https://doi.org/10.3389/fpubh.2023.1174638

4. Yu RT, Punzalan KAP, Bhatnagar S, Lutero RB, Chamen IMS, Masangkay CB, Arcellana-Nuqui EY. Seroreactivity of antibodies to hepatitis B core antigen among hepatitis B surface antigen-screened negative blood donors and its implications for blood safety in a resource-constrained country. Vox Sang. 2024;119(3):252-256. https://doi.org/10.1111/vox.13576

5. Fu MX, Ingram J, Roberts C, Nurmi V, Watkins E, Dempsey N, Golubchik T, Breuer J, Brailsford S, Irving WL, Andersson M, Simmonds P, Harvala H. Blood donation screening for hepatitis B virus core antibodies: The importance of confirmatory testing and initial implication for rare blood donor groups. Vox Sang. 2024;119(5):447-459. https://doi.org/10.1111/vox.13608

6. Allain JP, Mihaljevic I, Gonzalez-Fraile MI, Gubbe K, Holm-Harritshøj L, Garcia JM, Brojer E, Erikstrup C, Saniewski M, Wernish L, Bianco L, Ullum H, Candotti D, Lelie N, Gerlich WH, Chudy M. Infectivity of blood products from donors with occult hepatitis B virus infection. Transfusion. 2013;53(7):1405-1415. https://doi.org/10.1111/trf.12096

7. Delghandi S, Raoufinia R, Shahtahmasbi S, Meshkat Z, Gouklani H, Gholoobi A. An overview of occult hepatitis B infection (OBI) with emphasis on HBV vaccination. Heliyon. 2024;10(17):e37097. https://doi.org/10.1016/j.heliyon.2024.e37097

8. World Health Organization. Blood safety and availability [Internet]. Geneva: World Health Organization; 2023. https://www.who.int/news-room/fact-sheets/detail/blood-safety-and-availability

9. Morales J, Fuentes-Rivera J, Delgado-Silva C, Matta-Solís H. Marcadores de infección para hepatitis viral en donantes de sangre de un hospital nacional de Lima Metropolitana. Rev Peru Med Exp Salud Publica. 2017;34(3):466-471. https://doi.org/10.17843/rpmesp.2017.343.2503

10. Ortega Chavarría MJ, Ahumada Zavala SN, Díaz Greene E, Rodríguez Weber F. Prevalencia de hepatitis B y C en donadores de sangre de un hospital privado. Acta Méd Grupo Ángeles. 2020;18(3):246-250. https://www.medigraphic.com/cgi-bin/new/resumenI.cgi?IDARTICULO=95940

11. Silva SM, Oliveira MB, Martinez EZ. Distribution of serological screening markers at a large hematology and hemotherapy center in Minas Gerais, Southeastern Brazil. Rev Bras Hematol Hemoter. 2016;38(3):206-213. https://doi.org/10.1016/j.bjhh.2016.05.005

12. Rebouças KAAF, Narici FM, Santos Junior MN, Neres NSM, Oliveira MV, Souza CL. Seroprevalence of transfusion-transmissible infectious diseases at a hemotherapy service located in southwest Bahia, Brazil. Hematol Transfus Cell Ther. 2019;41(4):324-328. https://doi.org/10.1016/j.htct.2019.03.007

13. Ministerio de Salud de la Nación. Boletín N°6 - Hepatitis virales. 2024. https://www.argentina.gob.ar/sites/default/files/2024/07/boletin_hepatitis_virales_n6_2024.pdf

14. Marquez Roa NA, Lemir de Zelada MO, Molas AC. Frecuencia serológica de infección por Trypanosoma cruzi en donantes de sangre en el Paraguay entre los años 2006 y 2011. Mem Inst Investig Cienc Salud. 2013;11(2):26-31. https://revistascientificas.una.py/index.php/RIIC/article/view/1756

15. Rodríguez-Leiva RR, Rios-González CM. Seroprevalencia de marcadores para infecciones transmisibles por transfusión en donantes de un hospital de referencia nacional de Paraguay, 2016. Mem Inst Investig Cienc Salud. 2020;18(1):61-68. https://revistascientificas.una.py/index.php/RIIC/article/view/555

16. Ye X, Li T, Yu B, Zeng J, Shi Y, Xie H, Branch DR, Loriamini M, Li B, Chen L. The high prevalence of occult hepatitis B infections among the partners of chronically infected HBV blood donors emphasizes the potential residual risk to blood safety. J Med Virol. 2023;95(8):e29006. https://doi.org/10.1002/jmv.29006

17. Conti G, Notari EP 4th, Dodd RY, Kessler D, Custer B, Bruhn R, Reik R, Yang H, Whitaker BI, Stramer SL. Changes in transfusion-transmissible infection prevalence and demographics among US blood donors during the COVID-19 pandemic. Transfusion. 2024;64(6):1040-1049. https://doi.org/10.1111/trf.17851

Downloads

Published

06/11/2026

Issue

Section

Original Articles

How to Cite

1.
Navarro N, Samudio M, Marqués Roa N, et al. Trend in seroprevalence of hepatitis B virus markers in donors from Paraguay from 2012 to 2023. A retrospective approach at the national level. Med Clín Soc. 2026;10(1):e615. doi:10.52379/mcs.v10.615